According to the most recent research study, the global Respiratory Diagnostics Market size and share was valued at approximately USD 8.2 billion in 2021, is expected to reach USD 9.1 billion in 2022, and is expected to reach approximately USD 13.80 billion by 2030, at a compound annual growth rate (CAGR) of approximately 8.5% from 2022 to 2030.
Respiratory disease testing panel is a lyophilised test on Nobelza lab on chip that is capable of detecting and identifying bacteria, viruses, and fungi that can cause respiratory infections. It can assist in the diagnosis of respiratory infections such as influenza, pneumonia, and tuberculosis. It can detect multiple pathogens at a single time, making it superior to current testing methods that detect only one pathogen at a time.
Respiratory disease testing panel lyophilised on Nobelza chip should be used in association with Nobelza RT-PCR machine to simultaneously detect up to 4 different pathogens in a single reaction. The pathogens can be
•Viruses like Influenza A & B, Respiratory Syncytial virus, Adenovirus, SARS Covid etc.
•Bacteria infections caused by Streptococcus, Mycoplasma, Mycobacterium etc.
Patients with conditions ranging from mild to severe asthma, bronchitis, coughing, wheezing, shortness of breath and pneumonia. A respiratory disease testing panel can help to identify the cause of symptoms, and help to determine the best course of treatment.
To test for respiratory disease, a sample of a person's respiratory secretions, such as sputum or nasal swab, is collected and tested for the presence of a virus or other pathogen. The sample is first treated with a reagent that isolates the genetic material of the virus or pathogen, which is then amplified, or copied, for detection using the Nobelza platform
The result of Vector born disease testing panel becomes available in few hours after running the test. Negative result indicates that your symptoms were caused by a pathogen that was not tested for.